Metropolitan Life Insurance Co. NY Has $478,000 Position in DexCom, Inc. (DXCM)
Metropolitan Life Insurance Co. NY held its stake in DexCom, Inc. (NASDAQ:DXCM) during the first quarter, Holdings Channel reports. The fund owned 5,644 shares of the medical device company’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in DexCom were worth $478,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in DexCom during the first quarter valued at $136,000. Shell Asset Management Co. increased its stake in DexCom by 10.7% in the first quarter. Shell Asset Management Co. now owns 23,887 shares of the medical device company’s stock valued at $2,024,000 after buying an additional 2,314 shares during the period. Sit Investment Associates Inc. increased its stake in DexCom by 159.8% in the first quarter. Sit Investment Associates Inc. now owns 23,900 shares of the medical device company’s stock valued at $2,025,000 after buying an additional 14,700 shares during the period. Independent Portfolio Consultants Inc. increased its stake in DexCom by 97.6% in the first quarter. Independent Portfolio Consultants Inc. now owns 2,490 shares of the medical device company’s stock valued at $211,000 after buying an additional 1,230 shares during the period. Finally, Mn Services Vermogensbeheer B.V. increased its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the period.
Shares of DexCom, Inc. (NASDAQ:DXCM) traded down 0.29% on Friday, hitting $69.60. 940,650 shares of the stock were exchanged. The company’s market cap is $6.02 billion. DexCom, Inc. has a 12 month low of $57.68 and a 12 month high of $96.38. The company has a 50-day moving average price of $71.12 and a 200 day moving average price of $75.17.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the business earned ($0.24) EPS. Equities analysts forecast that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/13/metropolitan-life-insurance-co-ny-has-478000-position-in-dexcom-inc-dxcm.html.
Several equities research analysts have weighed in on the stock. BTIG Research downgraded shares of DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. Oppenheimer Holdings, Inc. set a $98.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Canaccord Genuity decreased their price target on shares of DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 3rd. B. Riley reaffirmed a “buy” rating and issued a $95.00 price target on shares of DexCom in a research note on Tuesday, May 2nd. Finally, BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $87.00.
In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $69.06, for a total transaction of $220,992.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 8,649 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total transaction of $591,505.11. Following the sale, the chief executive officer now owns 347,329 shares of the company’s stock, valued at $23,753,830.31. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,375 shares of company stock valued at $2,549,351. 1.70% of the stock is owned by company insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.